Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Johns Hopkins University: Clinical Trials & FDA Approval Profile

Johns Hopkins University (Baltimore, MD) sponsors 193 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 97 active protocols (66 recruiting now), 63 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.1%
Median Closed Enrollment vs National (145 pts)33 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Johns Hopkins University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)193
Active Pipeline (Recruiting Now)97 (66)
Completed vs Stopped Early63 / 33 (17.1%)
Median Closed Actual Enrollment33 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Johns Hopkins University
Hospital Research SiteLocationShared Protocols
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MD165
Sibley Memorial HospitalWashington D.C, DC8
Huntsman Cancer Institute at University of UtahSalt Lake City, UT7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Johns Hopkins University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07228104Adjuvant Steroid Outcomes in Idiopathic Subglottic StenosisPhase IIIRECRUITING
NCT05836987The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial FibrillationPhase IIIRECRUITING
NCT05537220Oral N-acetylcysteine for Retinitis PigmentosaPhase IIIACTIVE NOT RECRUITING
NCT04323800Convalescent Plasma to Stem Coronavirus (CSSC-001)Phase IICOMPLETED
NCT03535675Muscadine Plus (MPX) In Men With Prostate CancerPhase IIITERMINATED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johns Hopkins Medicine across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Johns Hopkins University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI